Long-Term Outcomes of BRAF-MEK Inhibitor Combinations

Author(s):

Panelists discuss recent data on progression-free survival (PFS) and duration of response (DOR) for BRAF-MEK inhibitor combinations, including encorafenib + binimetinib and dabrafenib + trametinib, while also addressing emerging safety signals, differences in response based on treatment lines, and considerations for dose modifications and sequencing strategies in clinical practice.

All: Please discuss the recent data on PFS and DOR for BRAF-MEK inhibitors combinations.
1. Encorafenib + binimetinib (Riely GJ, et al. J Clin Oncol. 2023)
2. Dabrafenib + trametinib (Planchard D, et al. J Thorac Oncol. 2022)
Have any new safety signals emerged from long-term follow-up?
1. Encorafenib + binimetinib (Smit E, et al. 2024.WCLC. MA06.13
2. Encorafenib + binimetinib (Riely G, et al. 2024.ESMO.LBA56)
  1. Impression of overall survival data
  2. Impact on clinical practice
  3. Difference in responses in first line vs second line
How do you choose between different BRAF-MEK inhibitor
Based on the recent data presented at ESMO, how do you approach dose modifications?
First-line immunotherapy vs BRAF and MEK inhibitors (Di Federico A, et al. 2024. ESMO. Abstract 1299p)
Treatment sequences in BRAF-V600 mutant (Wiesweg M, et al. 2024. ESMO Abstract 1300p